What the FDA labels say about taking them together
Epinephrine and velaglucerase alfa
Velaglucerase alfa's FDA label of November 26, 2024 names epinephrine in its boxed warning section; the epinephrine labels PlainMeds reads (4) do not name velaglucerase alfa. The velaglucerase alfa label: “… and immediately initiate appropriate medical treatment, including use of epinephrine.”
Check it at the source: the epinephrine FDA label on DailyMed (effective July 13, 2026, A-S Medication Solutions); the velaglucerase alfa FDA label on DailyMed (effective November 26, 2024, Takeda Pharmaceuticals America, Inc.).
What does the epinephrine label say about velaglucerase alfa?
Epinephrine's label (effective July 13, 2026) and its 3 other brand-application labels do not name velaglucerase alfa in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Epinephrine), A-S Medication Solutions, effective July 13, 2026 (SPL set 6e811e28-0199-4df7-a916-5940c632401d), via openFDA; the full label on DailyMed
What does the velaglucerase alfa label say about epinephrine?
Velaglucerase alfa label, boxed warningAnaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. ( 5.1 ) Initiate VPRIV in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. ( 5.1 ) If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue VPRIV and immediately initiate appropriate medical treatment, including use of epinephrine.
Velaglucerase alfa label, warnings and precautionsIf a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue VPRIV and immediately initiate appropriate medical treatment, including use of epinephrine.
Source: FDA drug label (VPRIV), BLA022575 (Shire Human Genetic), as published by Takeda Pharmaceuticals America, Inc., effective November 26, 2024 (SPL set ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Epinephrine | Velaglucerase alfa | |
|---|---|---|
| Labeled for | Asthma | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $123.51 per unit 0.15 mg auto-injct | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once